Ion Channel Mutation Detection for Sudden Cardiac Death Diagnosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic methods are inadequate for identifying the underlying causes of sudden cardiac death, particularly in cases involving ion channel mutations, which are associated with conditions like short QT syndrome, Brugada syndrome, Long QT syndrome, and progressive conduction disease, limiting effective preventive measures and treatment options.
Innovation Solution
Identification of previously unknown mutations in genes such as KCNH2, SCN5A, and KCNQ1, along with the development of nucleic acid probes and antibodies that selectively hybridize or bind to these mutant proteins, enabling diagnosis and screening for susceptibility to cardiac death and guiding treatment with specific drugs.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current diagnostic methods are used, then general cardiac conditions can be detected, but ion channel mutations causing sudden cardiac death cannot be identified
Solution Approach 1:
The diagnostic approach is segmented into multiple components: (1) detection of specific ion channel mutations (KCNH2, SCN5A, KCNQ1 genes), (2) identification of associated syndromes (Short QT, Brugada, Long QT), and (3) targeted treatment selection. This segmentation allows the diagnostic system to specifically target previously undetectable genetic mutations while maintaining overall diagnostic structure.
Solution Approach 2:
The patent introduces genetic testing as an intermediary diagnostic tool between conventional ECG findings and definitive diagnosis. By detecting specific mutations in ion channel genes, the intermediary test bridges the gap between observable cardiac symptoms and underlying genetic causes, enabling precise identification of mutation-related conditions.
2Reliability
If genetic screening for all ion channel mutations is performed, then comprehensive diagnosis is achieved, but diagnostic complexity and cost increase
Solution Approach 1:
Instead of uniform screening for all possible cardiac genetic mutations, the patent applies local quality by targeting specific mutations in specific genes (KCNH2 for Short QT syndrome, SCN5A for Brugada syndrome, KCNQ1 for Long QT syndrome) based on clinical presentation. This focused approach maintains diagnostic completeness for mutation-related conditions while reducing unnecessary complexity.
Solution Approach 2:
The diagnostic system changes parameters by focusing on specific genetic markers rather than broad screening. By identifying particular mutations (e.g., specific nucleotide changes in KCNH2 exon 7) associated with specific syndromes, the system transforms the diagnostic parameter from general cardiac evaluation to precise genetic identification, improving reliability without proportional complexity increase.
3Adaptability or versatility
If conventional treatment approaches are used, then general cardiac care is provided, but targeted therapy for mutation-specific conditions is not available
Solution Approach 1:
The patent implements preliminary action by performing genetic testing and identifying specific mutations before finalizing treatment plans. By detecting mutations in ion channel genes early in the diagnostic process, the system prepares targeted treatment strategies in advance, allowing customization of therapy based on the specific genetic defect before treatment begins.
Solution Approach 2:
The diagnostic system incorporates feedback by using genetic test results to guide and adjust treatment decisions. The information from mutation detection (e.g., KCNH2 mutations indicating Short QT syndrome) feeds back into the clinical decision-making process, enabling physicians to select treatments specifically appropriate for the identified genetic condition rather than using generic cardiac protocols.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for early diagnosis and targeted treatment of ion channel-related cardiac disorders, potentially reducing mortality risk by identifying genetic mutations associated with arrhythmias and sudden cardiac death.
Implementation Method 1
development of nucleic acid probes and antibodies that selectively hybridize or bind to these mutant proteins
Implementation Method 2
development of nucleic acid probes and antibodies that selectively hybridize or bind to these mutant proteins
Data Source
AI summary
Previously unknown mutations of the KCNH2, SCN5A and KCNQ1 genes are disclosed which are involved in ion channel disruptions associated with short QT syndrome, long QT syndrome, Brugada syndrome and progressive conduction disease. These mutations are utilized to diagnose and screen for short QT syndrome, long QT syndrome, Brugada syndrome and progressive conduction disease, thus providing modalities for diagnosing sudden cardiac death and/or predicting susceptibility to sudden cardiac death. Nucleic acid probes are provided which selectively hybridize to the mutant nucleic acids described herein. Antibodies are provided which selectively bind to the mutant proteins described herein. The mutations described herein are also utilized to screen for compounds useful in treating the symptoms manifest by such mutations.